|
|
Post by awesomo on Apr 9, 2020 7:04:18 GMT -5
So their website blows, and they have no articles, PR, etc. on search engine results that associate team members to the company...
|
|
|
|
Post by goyocafe on Apr 9, 2020 7:08:28 GMT -5
So their website blows, and they have no articles, PR, etc. on search engine results that associate team members to the company... That’s certainly one way to look at it, but why go out of the way to keep a website/web page off the search results? As always, more questions than answers. |
|
|
|
Post by awesomo on Apr 9, 2020 7:59:07 GMT -5
So their website blows, and they have no articles, PR, etc. on search engine results that associate team members to the company... That’s certainly one way to look at it, but why go out of the way to keep a website/web page off the search results? As always, more questions than answers. It doesn’t look intentional, it’s just a bad website with poor SEO and little company presence. I mean, it shows up when you specifically search “immix biopharma”. |
|
|
|
Post by goyocafe on Apr 9, 2020 9:11:19 GMT -5
That’s certainly one way to look at it, but why go out of the way to keep a website/web page off the search results? As always, more questions than answers. It doesn’t look intentional, it’s just a bad website with poor SEO and little company presence. I mean, it shows up when you specifically search “immix biopharma”. Actually, the search result for “Immix Biopharma” yields a “No information is available” with the following explanation support.google.com/webmasters/answer/7489871?hl=enThis is my site You are probably seeing this result for one of the following reasons: The page is blocked by robots.txt Description You have a rule in your site's robots.txt file* that prevents Google from reading the page (which is how we generate a description in search results). However, this doesn't prevent Google from showing the page in Search results. Therefore if the page appears in Search results, it will appear without any description. * A robots.txt file is a standard file that websites use to prevent search engines from crawling specific pages on their site. Some site hosting services create this file automatically for their customers. The next section describes how to confirm that this file is present, and that this is the issue. I’m not disagreeing with you about the site. I’m just pointing out that it might be intentional. Btw,It also doesn’t have any terms of use or copyright indicator which is also unusual. |
|
|
|
Post by rfogel on Apr 9, 2020 9:27:50 GMT -5
So their website blows, and they have no articles, PR, etc. on search engine results that associate team members to the company... At least I can find their pipeline -- immixbio.com/pipeline -- which is more than I can do on Mannkind's website. |
|
|
|
Post by goyocafe on Apr 9, 2020 9:31:17 GMT -5
So their website blows, and they have no articles, PR, etc. on search engine results that associate team members to the company... At least I can find their pipeline -- immixbio.com/pipeline -- which is more than I can do on Mannkind's website. Only if you browse to it from their website. Good luck searching for it on Google. |
|
|
|
Post by peppy on Apr 9, 2020 9:37:00 GMT -5
Here is an inappropriate post from me in this thread, surprise. For the last month, I have been thinking Merck. Merck on my mind, I went to the Merck website, looking at their vaccines, hoping I would find the reason Merck would now.... MNKD Which leads me to this. Another old anti parasite sitting on the shelf. MERCK. Ivermectin is a member of the avermectin class of broad-spectrum antiparasitic agents which have a unique mode of action. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). The selective activity of compounds of this class is attributable to the facts that some mammals do not have glutamate-gated chloride channels and that the avermectins have a low affinity for mammalian ligand-gated chloride channels. In addition, ivermectin does not readily cross the blood-brain barrier in humans. Ivermectin is active against various life-cycle stages of many but not all nematodes. It is active against the tissue microfilariae of Onchocerca volvulus but not against the adult form. Its activity against Strongyloides stercoralis is limited to the intestinal stages. Clinical Studies Strongyloidiasis DOSAGE AND ADMINISTRATION Strongyloidiasis The recommended dosage of STROMECTOL for the treatment of strongyloidiasis is a single oral dose designed to provide approximately 200 mcg of ivermectin per kg of body weight. See Table 1 for dosage guidelines. Patients should take tablets on an empty stomach with water. (See CLINICAL PHARMACOLOGY, Pharmacokinetics.) In general, additional doses are not necessary. However, follow-up stool examinations should be performed to verify eradication of infection. (See CLINICAL PHARMACOLOGY, Clinical Studies.) www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdfMERCK 5000% fold reduction in viral load in 48% www.sciencedirect.com/science/article/pii/S0166354220302011 |
|
|
|
Post by agedhippie on Apr 9, 2020 10:07:21 GMT -5
Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
www.routledge.com/search?pg=1&kw=Vladimir Torchilin&sb=NAN&so=pub&pp=12&view=list&pd=published&publishedFilter=3mo
Ok, and? Like I said, Google his name, I went down to page 4 of the results and still didn’t see Immix mentioned once. He’s distinguished, but clearly he is barely associated with Immix and/or Immix is insignificant. www.google.com/search?q=vladimir+torchilinHe is the name. If you are a startup or small company looking for funding you need a person with a name in the field to get the investors interested. In the case of Immix they have Series A funding so they are barely off the ground. My guess would be that the drugs are from existing university research that they are looking to commercialize. They were given the funding back in 2017 to get IMX-110 through Phase 1b trials, and issued a convertible note at the end of last year to fund US Phase 1b/2a trials so my guess is that they do not have much free cash. |
|
|
|
Post by mango on Apr 9, 2020 12:06:22 GMT -5
IR told me via email that Immix wants the drugs to be confidential for now. I'm assuming we won't know what they are doing until Phase 1 ready.
|
|
|
|
Post by goyocafe on Apr 9, 2020 13:27:24 GMT -5
IR told me via email that Immix wants the drugs to be confidential for now. I'm assuming we won't know what they are doing until Phase 1 ready. That sounds so much like RLS that my stomach turned when I read it.  |
|
|
|
Post by lennymnkd on Apr 9, 2020 13:37:15 GMT -5
United therapeutics is keeping it a secret as well /
|
|
|
|
Post by cjm18 on Apr 9, 2020 13:54:42 GMT -5
IR told me via email that Immix wants the drugs to be confidential for now. I'm assuming we won't know what they are doing until Phase 1 ready. That’s fine as long as $ and terms in the collaboration isn’t confidential. So far it’s a big fat zero $ |
|
|
|
Post by agedhippie on Apr 9, 2020 15:28:14 GMT -5
IR told me via email that Immix wants the drugs to be confidential for now. I'm assuming we won't know what they are doing until Phase 1 ready. That’s fine as long as $ and terms in the collaboration isn’t confidential. So far it’s a big fat zero $ It's likely that there is no money involved given the finding status of Immix. |
|
|
|
Post by cretin11 on Apr 9, 2020 18:46:44 GMT -5
This sounds almost as promising as the Torrey Pines collaboration.
|
|
|
|
Post by agedhippie on Apr 9, 2020 21:43:08 GMT -5
That’s fine as long as $ and terms in the collaboration isn’t confidential. So far it’s a big fat zero $ It's likely that there is no money involved given the finding status of Immix. Whoops, that should have been "funding status of Immix." |
|
